Prosecution Insights
Last updated: August 18, 2026

Sinai Health System

7 pending office actions • 6 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
4
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (43%)
4
Medium (57%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (29%)
Double-patenting + other2 (29%)
Multi-statute (no §101)3 (43%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WILSON, MICHAEL C 2 41.4% +17.5%
STEELE, AMBER D 1 59.0% +9.7%
KRISHNAN, GANAPATHY 1 52.4% +0.5%
NOLAN, JASON MICHAEL 1 66.3% -28.0%
LU, FRANK WEI MIN 1 62.6% +67.6%
SITTON, JEHANNE SOUAYA 1 53.0% +48.0%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18426877 Treatment of Homologous Recombination Deficient Cancers STEELE, AMBER D 4d overdue
18271089 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF NOLAN, JASON MICHAEL
15556146 TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS WILSON, MICHAEL C

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
16760522 CANCER DETECTION, CLASSIFICATION, PROGNOSTICATION, THERAPY PREDICTION AND THERAPY MONITORING USING METHYLOME ANALYSIS SITTON, JEHANNE SOUAYA 34d
17825784 TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS WILSON, MICHAEL C 79d
18059370 METHODS OF CAPTURING CELL-FREE METHYLATED DNA AND USES OF SAME LU, FRANK WEI MIN
15556146 TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS WILSON, MICHAEL C

Top Art Units

Art UnitApps
1638 2
1658 1
1693 1
1623 1
1683 1
1682 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18426877 Treatment of Homologous Recombination Deficient Cancers STEELE, AMBER D 1658 §103§112Other Final Rejection 4d overdue Pending Jan 30, 2024
18284614 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS KRISHNAN, GANAPATHY 1693 §103Other Non-Final OA 15d overdue Pending Sep 28, 2023
18271089 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF NOLAN, JASON MICHAEL 1623 §103§112 Non-Final OA Pending Jul 06, 2023
18059370 METHODS OF CAPTURING CELL-FREE METHYLATED DNA AND USES OF SAME LU, FRANK WEI MIN 1683 §102§103§112DP Non-Final OA Pending Nov 28, 2022
17825784 TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS WILSON, MICHAEL C 1638 §103§112DPOther Non-Final OA 79d Pending May 26, 2022
16760522 CANCER DETECTION, CLASSIFICATION, PROGNOSTICATION, THERAPY PREDICTION AND THERAPY MONITORING USING METHYLOME ANALYSIS SITTON, JEHANNE SOUAYA 1682 §103 Final Rejection 34d Pending Apr 30, 2020
15556146 TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS WILSON, MICHAEL C 1638 §103§112 Final Rejection Pending Sep 06, 2017

Managing Sinai Health System's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month